Skip to main content

Table 1 Comparisons of clinical and imaging characteristics of patients

From: Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity score analysis

Characteristic Before PSM After PSM
Chemotherapy + IRE Chemotherapy + radiotherapy Total number P value Chemotherapy + IRE Chemotherapy + radiotherapy Total number P value
Total number   36 40 76   36 36 72  
Age (years) ≤60 20 24 44 0.817 20 20 40 1.000
> 60 16 16 32 16 16 32
Gender Female 19 15 34 0.248 19 15 34 0.479
Male 17 25 42 17 21 38
Tumor size (cm) ≤2 1 2 3 0.623 1 2 3 0.790
2~4 20 18 38 20 18 38
>4 15 20 35 15 16 31
Tumor grade Well 3 5 8 0.763 3 5 8 0.633
Moderate 20 23 43 20 21 41
Poor 13 12 25 13 10 23
LN metastasis Absent 9 14 23 0.454 9 14 23 0.312
Present 27 26 53 27 22 49
Tumor site Head 18 18 36 0.498 18 16 34 0.562
Body 15 15 30 15 14 29
Tail 3 7 10 3 6 9
TNM stage IIB 4 9 13 0.232 4 8 12 0.343
III 32 31 63 32 28 60
WBC (*109) ≤10 32 37 69 0.702 32 33 65 0.989
> 10 4 3 7 4 3 7
HGB (g/L) ≤120 1 7 8 0.059 1 6 7 0.107
>120 35 33 68 35 30 65
PLT (*109) ≤300 31 34 65 0.978 31 31 62 1.000
>300 5 6 11 5 5 10
ALT (U/L) ≤40 26 31 57 0.608 26 28 54 0.786
> 40 10 9 19 10 8 18
AST (U/L) ≤40 29 34 63 0.762 29 31 60 0.753
>40 7 6 13 7 5 12
ALP (U/L) ≤100 19 28 47 0.158 19 25 44 0.227
>100 17 12 29 17 11 28
GGT (U/L) ≤45 19 22 41 0.935 19 20 39 1.000
>45 17 18 35 17 16 33
ALB (g/L) ≤40 4 4 8 0.957 4 4 8 1.000
>40 32 36 68 32 32 64
TBIL (umol/L) ≤20.5 27 33 60 0.574 27 30 57 0.563
>20.5 9 7 16 9 6 15
IBIL (umol/L) ≤15 32 39 71 0.184 32 35 67 0.357
>15 4 1 5 4 1 5
CRP (ng/L) ≤3 24 24 48 0.637 24 21 45 0.627
>3 12 16 28 12 15 27
CEA (ng/mL) ≤5 21 25 46 0.815 21 22 43 0.982
>5 15 15 30 15 14 29
CA19–9 (U/ml) ≤35 9 9 18 0.962 9 8 17 0.987
>35 27 31 58 27 28 55
Chemotherapy FOLFIRINOX 21 18 39 0.262 21 17 38 0.479
Gem 15 22 37 15 19 34
  1. IRE irreversible electroporation, LN lymph node metastasis, TNM tumor-node-metastasis stage, WBC white blood cell count, PLT platelet count, ALT alanine transaminase, AST aspartate aminotransferase, ALP alkaline phosphatase, GGT glutamyl transpeptidase, ALB albumin, TBIL total bilirubin, IBIL indirect bilirubin, CRP C-reactive protein, CEA carcinoembryonic antigen, CA19–9 carbohydrate antigen 19–9